Communicating with Your NCI Program Director: It's a Two-Way Street

Natalia Mercer, PhD



DCB NGWS, January 24th, 2024

Overview

- About us
 - Who we are
 - What we do (and don't)
- Connecting with your PD
 - When
 - Why

Office of the Director

Daniel Gallahan, Ph.D (Director) Shannon Hughes, Ph.D. (Deputy Director) Lisa Witzler, Ph.D. **Jason Bunting Yvette Butler Cancer Cell Biology Branch** Tamika Carney Rihab Yassin, Ph.D (Chief) Janice Embry Sharmistha Ghosh-Janjigian, Ph.D. **Tiffany Ferguson Riante Jones** Rebekah Mikeasky Konstantin Salnikow, Ph.D Claire McCarthy, Ph.D. Kristine Willis, Ph.D. **Michelle Turner**

Matthew Whitehead

Tumor Biology and Microenvironment Branch Jeffrey Hildesheim, Ph.D. (Chief) Tapan Bera, Ph.D. Christina George Mihoko Kai, Ph.D. Natalia Mercer, Ph.D. Elizabeth Woodhouse, Ph.D.

Ruibai Luo, Ph.D.

Stefan Maas, Ph.D.

Wanping Xu, Ph.D.

Tumor Metastasis Branch Joanna Watson, Ph.D. (Chief) Grace Ault, Ph.D. Justin Benavidez, Ph.D. Brunilde Gril, Ph.D. Christine Nadeau, Ph.D. Elizabeth Snyderwine, Ph.D. Fanta Whiting

Bridgette Tobiassen Eric Graves Kelly Dyott **Kevin Greene**

Linda Stephens Paige Walker

Biophysics, Bioengineering, and

Computational Sciences Branch

Jennifer Couch, Ph.D. (Chief)

Anowarul Amin, Ph.D.

Steven Becker, Ph.D.

Robin Brown

Eric Johnson Chavarria, Ph.D.

Jerry Li, M.D., Ph.D.

David Miller, Ph.D.

Hannah Dueck, Ph.D.

Cancer Immunology, **Hematology and Etiology Branch** Kevin Howcroft, Ph.D. (Chief) Phil Daschner **Yvonne Duglas-Tabor** Chamelli Jhappan, Ph.D Margaret Klauzinska, Ph.D. Lillian Kuo, Ph.D. Yin Liu, Ph.D. Elizabeth Read-Connole, Ph.D. Monica Zamisch, Ph.D. Zulekha Sayyed, MSHS

DNA and Chromosome Aberrations Branch lan Fingerman, Ph.D. (Chief) Ron Johnson, Ph.D. Paul Okano, Ph.D Anu Sharman, Ph.D. Michael Weinreich, Ph.D. Keren Witkin, Ph.D.

Our Division

ARC


PD roles

- **<u>Guidance</u>**: help the PI optimize the application, policy, funding mechanisms
- <u>Stewardship</u>: Ensure that the nation's investment in NCI is well-spent, in a legal and ethical manner.
- <u>Vision</u>: Be current and forward-looking about the big picture in our field, so we can help NIH leadership and PIs make decisions about how best to advance cancer research.
- We work together with PDs, SROs, and GMSs.
- Serve as a point of contact to Pls.
- Report major research advances to DCB colleagues and NCI/NIH leadership.
- Attend study sections.
- Work with GMS on administering grants:
 - both the PD and the GMS must hit the "GO" button to award a grant.
 - Review, evaluate, and approve annual progress reports.
 - Monitor compliance of regulations, policies, special terms of the award.

What NCI PDs cannot do for you...

- Tell you how to design your project.
- Provide exemptions for submission deadline or rulesviolation.
- Change a study section assignment.
- Change the NCI funding policy.
- Change the requirements that must be fulfilled for an award to be issued.
- Write you a letter of recommendation as your PD.
- Talk to your Chairperson, or *anyone* outside of NIH except you, about your application, your Summary Statement, or your job/position status.

When is a good time to connect?



Pre-submission

Finding the right PD

Tips and Tricks – NIH RePORTER

Research Portfolio Online Reporting Tools Search 9		 Use Matchmaker to find PDs with portfolios in your area 	
(BuPORT)	HOME ABOUT RHPORY EAQL GLOSSARY CONTACT	of research or to find funded projects like yours.	
CK UNKS RESEARCH ORGANIZATIONS W	INFORCE FUNDING REPORTS LINKS & DATA	of research of to find funded	projects like yours.
BattoBDDD > Gory Form	RePORTER Login Register RePORTER Manual System Pearly # 0822	TOTAL PROPERTY.	
		annya an farmanan annan	
BMT QUERY CLEAR QUERY	Floor Year (FY) Addise Projects	Precia Your (PT) () (mitter Progent Event ments some other Progent REGET ALLOCATE	Characters for York
ARCHER AND ORGANIZATION		S00 projects with similar concepts to the external text. (S00 maximum)	Child Reven In view ubstativel Charles
Project Leader (Lest Never, First Never) Une TV for wildcard in P1 nerves Enter Deviate P3Project Leader nerves CR P1 Profe IDs	City () Use "V for widdard dise: ()		STUDY SECTION
Ceganitation @ Prass enter grissed 3 characters to see Lockup, Contacts O Begre with O Dead	Country: () STATUT	100 UNITED	
Department Type:	DUNS Number 🕢	No. No. <td>The the volue only the most</td>	The the volue only the most
I SEARCH		Contact P() Solar T Ast. Project. Yes: End # Project Take Contact P() Project Lader Contact addres Contact addres Contact addres Contact addres Contact addres	PV Admin Funding PV Edual Mamber (K) (K) Continy (K) Property
• And	Amerika S. Lind Polyce Mark 20 Lind Polyce Amerika Polyce Lind Polyce 2 Mark 2019 1997 1997 1997 1997 1997 1997 1997 1	138 Program (Official) from the matched property. (30	0 projects maximum) California to one addar
ECT DETAILS		And	2 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Project Numberi Application 10 mar. 500:07472345.44 Use "N" for wildowd is provid number; e.g. 1982.1%	Agency/institute/Center.	Child on the outputs function for smaller	01 Malles 01 021 021 000 015 001 000 Records per page (25 9)
10/10/01 Enter multiple project multiples/application.iDa	NIH Spending Category: ()	Program Official	Contact Information Pro
	Funding Mechaniam:	SATURATING ALCORETING AUXT. OPAGE 3	N/1 CitoLis view PD annut address ND1 CitoLis view PD annut address
		GAO 338A8KB INDODENDARE RAGABETH	NP 6.61 Elskik unschilt adatate I NCI Elskik unschilt adatate
		South a sector of the sector o	NG1 CAR IS ON TO ANAL ARRAY
		INTERNAL ADDRESS AND ADDRESS A	New ENGLANDER, POLADARE AND ADDR
		ZAMIR JAATSAAN Z SATRAMAGUKTAT MEDIAAN	HC1 Child to see 20 and address HC1 Child constitutions
		BHEN GRADEL	MEX Club to case PO errori adultose MEX Elektron PO errori adultose

NIH NATIONAL CANCER INSTITUTE About Cancer < Cancer Types < Research < Grants & Training < News & Events < About NCI ~ Home > About NCl > NCl Organization > DCB > About DCB > Contact the Division of Cancer Biology DCB Contact the Division of Cancer Biology Research Portfolio > Division of Cancer Biology **Research Programs** > 9609 Medical Center Drive MSC 9747/9748 Bethesda, MD 20892 Funding > Researcher Resources Follow DCB on Twitter 🗷 News & Events > ON THIS PAGE About DCB Office of the Director Contact & Staff Cancer Cell Biology Branch Progress > Cancer Immunology, Hematology, and Etiology Branch DNA and Chromosome Aberrations Branch • Biophysics, Bioengineering, and Computational Sciences Branch Tumor Biology and Microenvironment Branch Tumor Metastasis Branch

Administrative Resource Center

Early discussions about:

- your ideas for an application,
- relevance to NCI mission,
- potential funding mechanisms and study sections,
- when to apply,
- budget policies,
- appropriate expertise, etc.

Post-submission

Post-review

- Discuss summary statements and potential next steps
- Discuss chances of funding

Pre-award phase

- Help resolve pre-award issues such as:
 - concerns with scientific overlap,
 - budget,

٠

- V. Animal/H. Subjects,
- foreign components.

Post-award phase

- Conversations about:
 - progress of your research grant, including your publications
 - compliance of regulations, policies, special terms of the award.
 - gaps/needs/opportunities in the project throughout the grant lifecycle.
 - additional sources of funding

And It's a Two-Way Street: PI responsibilities

- Update "Personal Profile" section of eRA Commons (e.g., name, degrees, institution, department, academic rank, address, phone number, email).
- Monitor status updates for applications and grants as they move through the system, via the "Status" section of eRA Commons.
 - Documents received/accepted, study section assignment and SRO, NIH referral assignment, NIH PD, Score, Summary Statement, Just-in-Time (JIT) requests, Notice of Award (NoA), etc.
- Submit required materials on time: Just-in-Time info, Progress Report (RPPR), required certifications and documentation (e.g., IACUC, IRB, training certification, data sharing, resource sharing, genomic data sharing, grant close-out reports).
- Inform PD about major advances and publications no need to wait for next Progress Report (optional, but easy).

Annual progress reports are required to document grantee accomplishments and compliance with the terms of the award.

Guidance:

- About 2 pages (3 max), including figures if appropriate.
- Highlight overall summary of progress followed by specific progress towards each Specific Aim, describing successes and challenges.
- Discuss plans for the next year.
- Include Supplement Progress Report if you have a Supplement.
- List <u>relevant</u> Publications, entering them into the NIH Public Access Policy system.
- Include any other assurances/certifications required for your award.
- Seek advice from colleagues on the science, and from Sponsored Research Office for guidance on the administrative sections.
- Take a day or two to prepare not an hour and not a week.

An Atypical Progress Report (RPPR)...

"Too much" data/progress

- Is this one year's progress? Does it distinguish between prior years' progress and the most recent year's progress?
- Is the progress from just this grant? Are some data from other funding, which may synergize with this project?
- "Too little" data/progress
 - Is this an accurate account of total progress for the year?
 - If so, is this a recurring issue? Discuss the challenges and plans to get back on track; determine any help the PD can provide, especially for New PIs.
 - If not, then PI will be requested to revise and provide sufficient information on progress and results.

We will reach out to you too!- keep an eye out for our emails

- grant related questions
- invitation to participate in a WS or a seminar
- inform you about programs relevant to your expertise
- notify you of other opportunities

Take home message: connect with your PD...

...and with the Division of Cancer Biology!



Visit our website!



NCI Division of Cancer Biology



@NCICancerBio

DCB Communications team Claire McCarthy, Ph.D. Riante Jones Rebekah Mikeasky



Subscribe to our newsletter (and other interest groups)!

Thank you for your attention!



www.cancer.gov/espanol

www.cancer.gov